Audrey joined Forbion in 2021 and is now a Principal contributing to building and managing the portfolio across therapeutic areas and modalities. In that capacity, she currently serves as board director on Azafaros and observer on CellCentric, Synox, Anaveon, Granite, and formerly Aiolos (Acquired by GSK).
Audrey started her career with Kurma Partners, a well-known management company based in Paris, specialised in the financing of innovation in healthcare and biotechnology. Prior to joining Forbion, Audrey was an Associate with Bpifrance – Large Venture, the Growth fund managed by the French Sovereign Wealth Fund. Audrey has experience with healthcare investment activities including sourcing, scientific and medical due diligence, valuation assessments, deal execution and portfolio management.
Audrey received her Masters in Biology from the University of Technology of Compiègne in France, and is a graduate of ESCP Europe with a major in Biopharmaceutical Management.
With Forbion I have the opportunity to get exposed to compelling projects alongside a dynamic team where everybody shares expertise and convictions with a common goal: supporting innovation in healthcare to impact patients’ lives.
Portfolio
Companies worked on by Audrey Cacaly
